nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

01.11.2012 | Review

Neuroenhancement strategies for psychiatric disorders: rationale, status quo and perspectives

verfasst von: Claus Normann, Christoph Nissen, Lukas Frase

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Sonderheft 2/2012

Einloggen, um Zugang zu erhalten

Abstract

With the growing mechanistic understanding of higher brain functions like learning and memory, vigilance and social cognition, new pharmacological approaches for the treatment of psychiatric disorders arise. Substances used as neuroenhancers for the improvement of cognitive or emotional functions in healthy subjects might provide novel pharmacological opportunities in psychiatry. Intriguingly, drugs like modafinil, d-cycloserine or oxytocin have shown significant improvements in key symptoms in several psychiatric disorders. When used as augmentation strategies, they could either directly interfere with psychopathological impairments or improve response to other treatment modalities like psychotherapy or psychopharmacological drugs. While initial studies yielded promising results, further research on beneficial or adverse effects is required.

Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, Jiang J, Greenhill L (2005) Efficacy and safety of Modafinil film-coated tablets in children and adolescents with attentiondeficit/hyperactivity disorder: results of a randomized, doubleblind, placebo-controlled, flexible-dose study. Pediatrics 6:777–784CrossRef

Bliss TV, Lomo T (1973) Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol 232:331–356CrossRefPubMedPubMedCentral

DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR (2003) Modafinil in Depression Study Group: Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo controlled study. J Clin Psychiatry 64:1057–1064CrossRefPubMed

Deroche-Gamonet V, Darnaudery M, Bruins-Slot L, Piat F, Le-Moal M, Piazza PV (2002) Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology 161:387–395CrossRefPubMed

Ditzen B, Schaer M, Gabriel B, Bodenmann G, Ehlert U, Heinrichs M (2009) Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict. Biol Psychiatry 65:728–731CrossRefPubMed

Fava M, Thase ME, DeBattista C (2005) A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 66:85–93CrossRefPubMed

Frye MA, Grunze H, Suppes T, McElroy SL, Keck PE Jr, Walden J, Leverich GS, Altshuler LL, Nakelsky S, Hwang S, Mintz J, Post RM (2007) A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 64:1242–1249CrossRef

Hebb DO (1949) The organization of behavior: a neuropsychological theory. Wiley, New York

Heim C, Young LJ, Newport DJ, Mletzko T, Miller AH, Nemeroff CB (2009) Lower CSF oxytocin concentrations in women with a history of childhood abuse. Mol Psychiatry 10:954–958CrossRef

10.

Holderbach R, Clark K, Moreau JL, Bischofberger J, Normann C (2007) Enhanced long-term synaptic depression in an animal model of depression. Biol Psychiatry 62:92–100CrossRefPubMed

11.

Hurlemann R, Patin A, Onur OA, Cohen MX, Baumgartner T, Metzler S, Dziobek I, Gallinat J, Wagner M, Maier W, Kendrick KM (2010) Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans. J Neurosci 30:4999–5007CrossRefPubMed

12.

Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E (2005) Oxytocin increases trust in humans. Nature 435:673–676CrossRefPubMed

13.

Myrick H, Malcolm R, Taylor B, Larowe S (2004) Modafinil: preclinical, clinical, and post-marketing surveillance—a review of abuse liability issues. Ann Clin Psychiatry 16:101–109CrossRefPubMed

14.

Ninan PT, Hassman HA, Glass SJ, McManus FC (2004) Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. J Clin Psychiatry 65:414–420CrossRefPubMed

15.

Onur OA, Schlaepfer TE, Kukolja J, Bauer A, Jeung H, Patin A, Otte DM, Shah NJ, Maier W, Kendrick KM, Fink GR, Hurlemann R (2010) The N-methyl-d-aspartate receptor co-agonist d-cycloserine facilitates declarative learning and hippocampal activity in humans. Biol Psychiatry 67:1205–1211CrossRefPubMed

16.

Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M (2004) Cognitive enhancers as adjuncts to psychotherapy: use of d-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61:1136–1144CrossRefPubMed

17.

Swanson JM, Greenhill LL, Lopez FA, Sedillo A, Earl CQ, Jiang JG, Biederman J (2006) Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 1:137–147CrossRef

18.

Thase ME, Fava M, DeBattista C, Arora S, Hughes RJ (2006) Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr 2:93–102CrossRef

19.

Whitlock JR, Heynen AJ, Shuler MG, Bear MF (2006) Learning induces long-term potentiation in the hippocampus. Science 313:1093–1097CrossRefPubMed

20.

Xu L, Anwyl R, Rowan MJ (1997) Behavioural stress facilitates the induction of long-term depression in the hippocampus. Nature 387:497–500CrossRefPubMed

21.

Zobel I, Werden D, Linster H, Dykierek P, Drieling T, Berger M, Schramm E (2010) Theory of mind deficits in chronically depressed patients. Depress Anxiety 27:821–828CrossRefPubMed

Titel: Neuroenhancement strategies for psychiatric disorders: rationale, status quo and perspectives
verfasst von: Claus Normann
Christoph Nissen
Lukas Frase
Publikationsdatum: 01.11.2012
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe Sonderheft 2/2012
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-012-0356-1

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Neuroenhancement strategies for psychiatric disorders: rationale, status quo and perspectives

Abstract

Neu im Fachgebiet Psychiatrie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

So wirken verschiedene Alkoholika auf den Blutdruck

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Update Psychiatrie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2012

Translocator protein (18 kDa) (TSPO) as a therapeutic target for anxiety and neurologic disorders

Multimodal functional and structural imaging investigations in psychosis research

Auditory verbal hallucinations: imaging, analysis, and intervention

Chances and risks of predicting psychosis

Rationale and content of psychenet: the Hamburg Network for Mental Health

Stress, burnout, and job dissatisfaction in mental health workers

Neu im Fachgebiet Psychiatrie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

So wirken verschiedene Alkoholika auf den Blutdruck

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Update Psychiatrie